Activity Dates: 04/19/2009 - 04/19/2012
This course is closed. Please look for other available products in CPNP University.
If you are a pharmacist, nurse practitioner or other healthcare professional involved in the comprehensive medication management of psychiatric and/or neurological patients, we invite you to participate in this online course.
Suicide is considered rare in non-depressed individuals but it occurs in between 5 and 15% of those suffering from depression. The Columbia Suicide Severity Rating Scale (C-SSRS) is recommended for assessing an individual patient’s suicide risk. Suicide risk factors in children, adolescents and adults include untreated depression, psychosis, access to firearms. Additional factors that increase suicide risk in children and adolescents include maternal depression, witnessing suicide attempts or sexual abuse or experiencing sexual abuse or trauma themselves. Cyber-bullying is becoming more recognized as a contributing factor to suicide in youth.
In 2004, the FDA applied warnings to antidepressants regarding an increased risk of suicidal thoughts and behaviors in children and adolescents. In 2007, the FDA revised this warning to inform consumers that untreated depression or other mental illnesses also increase the risk for suicide. Increased suicidality associated with antidepressant use may be related to increased energy from the antidepressant before the mood is improved or it may be a result of drug-induced activation, impulsivity or a switch from depression to mania or hypomania.
Antidepressant therapy is an effective and safe treatment option for adolescent depression with careful monitoring and counseling. Fluoxetine, sertraline, citalopram and escitalopram all have evidence to support their use as first-line treatments for depression in adolescents. Results are less robust for pre-pubertal children although fluoxetine is FDA approved down to 8 years old. Venlafaxine has been demonstrated as an effective treatment option for resistant depression in adolescents. Cognitive behavioral therapy is also an effective treatment option that may offer a protective “anti-suicide” effect. Psychosocial interventions are recommended for very young children as well as maintaining a watchful, waiting approach.
You will proceed through the following steps to satisfactorily complete this course:
This course is provided online at cpnp.org and consists of the speaker audio and slides. A PDF file of the slides is also provided and access is available to participants indefinitely although ACPE credit is available only through the course expiration date.
Participants in this course must complete an examination and achieve a score of 60% or greater. Successful completion of the course also requires the completion of a course evaluation. ACPE statements of credit can be retrieved by participants online at cpnp.org immediately upon successful completion of the course.
CPNP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access CPNP course materials online, you will need:
CPNP web sites no longer fully support Microsoft Internet Explorer 9 and older or Windows Vista and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Julie Dopheide, PharmD, BCPP
Steve Stoner, PharmD, BCPP
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This self-study course provides 2.0 contact hours (0.2 CEUs) of knowledge-based continuing education credit from CPNP approved programming. The ACPE universal program numbers assigned to this course are 0284-0000-09-003-H01-P and 0284-0000-09-002-H01-P (2.0 contact hours).
ACPE approved contact hours are accepted for ANCC Certification Renewal (see pages 5 and 6): At least 50% (37.5 hours) of your 75 continuing education hours must be formally approved continuing education hours. Formally approved continuing education hours meet one or more of the criteria listed below:
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information and disclosures). The opinions expressed in the educational activity do not necessarily represent the views of CPNP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: Potential off-label uses of antidepressant medications in the therapeutic classes of monoamine oxidase inhibitors, tricyclic antidepressants, SSRI?s, SNRI?s and other agents in non-specific classes. Antidepressants (sertraline, citalopram, escitalpram, venlafaxine, duloxetine, bupropion, mirtazapine) off-label in children and adolescents for managing depression.
This programming was supported in part by grants from Bristol-Myers Squibb, Forest Laboratories, Inc., Lilly, Schering-Plough, Cyberonics, Shire, and Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. administered by Ortho-McNeil Janssen Scientific Affairs, LLC.
Supported by an educational grant from Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. administered by Ortho-McNeil Janssen Scientific Affairs, LLC.